Skip to main content
Ipsen Home Page
Press shift tab to select search category

Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category

    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • emc易倍官网入口Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • emc易倍官网入口 Australia
    • emc易倍官网入口 China
    • emc易倍官网入口 Singapore
    • emc易倍官网入口 South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • emc易倍官网入口 Nordics
    • Greece
    • Italy
    • Netherlands
    • emc易倍官网入口 Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • emc易倍官网入口Company
    • emc易倍官网入口Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • emc易倍官网入口Oncology
    • emc易倍官网入口Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • emc易倍官网入口Oncology
      • Rare Disease
      • emc易倍官网入口Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • emc易倍官网入口Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Press Releases

emc易倍官网入口

emc易倍官网入口

Topics

Period

recent search

Reset

Showing: 1 – 05 of 246 Press Releases

19 May 2026

19 May 2026

Download Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity
Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity

16 May 2026

16 May 2026

Download Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

15 May 2026

15 May 2026

Download Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC
Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

14 May 2026

14 May 2026

Download Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium

23 April 2026

23 April 2026

Download Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Ipsen Q1 2026 Press Release Download (251.12 KB)

Ipsen Q1 2026 Highlights Download (404.22 KB)

Ipsen Q1 2026 Investor presentation Download (1.05 MB)


  • 1
  • 2
  • …
  • 50
Your dedicated contacts
Sally Bain

Head of Global Media Relations

  • Phone Number
  • +1 857 320 0517
  • Email Address
  • sally.bain@ipsen.com

Anne Liontas

France Media Relations

  • Phone Number
  • +33 7 67 34 72 96
  • Email Address
  • anne.liontas.ext@ipsen.com

Stay updated
  • Register to receive our latest news

IPN price

€159.60

 €2.00 (1.27%)

  • emc易倍官网入口Media Resources
  • Annual Report
  • Contacts
  • Our Locations

Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-05-21 5:50:53